Use of temozolomide instead of cyclophosphamide in diffuse large B-cell lymphoma

Leuk Lymphoma. 2016;57(3):724-5. doi: 10.3109/10428194.2015.1070152. Epub 2015 Aug 13.

Authors

T Cassou-Mounat¹, V Delwail², E Cayssials², M Terroir³, M Puyade²

Affiliations

¹ a Department of Nuclear Medicine , Hospital St Antoine APHP, UPMC Paris , 184 rue du Fg St Antoine, 75012 Paris , France.
² b Department of Haematology , CHU Poitiers , 2 rue de la Miletrie, 86000 Poitiers , France.
³ c Department of Nuclear Medicine , Gustave Roussy , 114 rue Edouard Vaillant, 94805 Villejuif , France.

PMID: 26148876
DOI: 10.3109/10428194.2015.1070152

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biopsy
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Dacarbazine / administration & dosage
Dacarbazine / analogs & derivatives
Drug Hypersensitivity
Drug Substitution*
Fatal Outcome
Fluorodeoxyglucose F18
Humans
Immunophenotyping
Lymphoma, Large B-Cell, Diffuse / diagnosis
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Positron Emission Tomography Computed Tomography
Recurrence
Temozolomide
Treatment Outcome
Young Adult

Substances

Fluorodeoxyglucose F18
Dacarbazine
Cyclophosphamide
Temozolomide